What development phase is ERSOFERMIN in?

ERSOFERMIN is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ERSOFERMIN

FDA-approved active Recombinant protein Quality 6/100

At a glance

Generic name	ERSOFERMIN
Modality	Recombinant protein
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ERSOFERMIN CI brief — competitive landscape report
ERSOFERMIN updates RSS · CI watch RSS